Standardized Added Metabolic Activity Predicts Survival after Intra-arterial Resin-Based 90Y Radioembolization Therapy in Unresectable Chemorefractory Metastatic Colorectal Cancer to the Liver

Faramarz Edalat, Juan C. Camacho, Nima Kokabi, Ayse Tuba Kendi, James R. Galt, Hyun S. Kim

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Purpose Standardized added metabolic (SAM) activity is a functional objective measurement of the total tumoral metabolic activity that avoids partial volume effect and thresholding, which limit conventional PET parameters. The purpose of this study is to investigate the role of SAM in predicting survival in unresectable, chemorefractory colorectal hepatic metastatic disease treated with resin-based 90Y radioembolization. Materials and Methods This is a prospective correlative study of patients with unresectable, chemorefractory colorectal liver metastasis who underwent 18F-FDG PET/CT and CT/MRI before and after 90Y. Target RECIST, PERCIST, change in total glycolytic activity (ΔTGA), and ΔSAM treatment response were assessed. Percentage changes in diameter, SUVpeak, TGA, and SAM were calculated pre-and post-90Y therapy and objective response was defined as >30% change (responders). Survival analysis by Kaplan-Meier, log-rank, and Cox proportional hazard models were performed and significance was set at <0.05. Results Sixteen patients (mean age of 61.6) were enrolled and performed a total of 20 90Y therapies. After 90Y, target ΔSAM showed an objective response rate of 40% vs. 35%, 30%, and 22.2% based on target ΔTGA, PERCIST, and RECIST criteria, respectively. Median overall survival (OS) of the cohort after 90Y was 9.2 months (CI 95% 2.2-16.2). Patients demonstrating objective response based on ΔSAM had a median OS of 22.7 months (CI 95% 12.4-33.0) vs. 6.7 (CI 95% 4.2-9.2) in non-responders (P = 0.007). On multivariate analysis, hazard ratios for the objective response group based on target ΔSAM were 0.01 (P = 0.03) vs. 0.05 (P = 0.08), 0.20 (P = 0.29), and 0.91 (P = 0.98) based on target ΔTGA, PERCIST, and RECIST criteria, respectively. Conclusions In unresectable colorectal liver metastatic disease refractory to standard chemotherapy, ΔSAM predicted OS for assessment of response following 90Y radioembolization therapy, whereas RECIST, PERCIST, and ΔTGA did not.

Original languageEnglish (US)
Pages (from-to)e76-e81
JournalClinical nuclear medicine
Volume41
Issue number2
DOIs
StatePublished - Feb 1 2016
Externally publishedYes

Fingerprint

Liver Neoplasms
Colorectal Neoplasms
Survival
Liver
Fluorodeoxyglucose F18
Therapeutics
Survival Analysis
Proportional Hazards Models
Liver Diseases
Multivariate Analysis
Prospective Studies
Neoplasm Metastasis
Drug Therapy
Response Evaluation Criteria in Solid Tumors

Keywords

  • Y radioembolization
  • colorectal cancer
  • PET
  • standardized added metabolic activity

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Standardized Added Metabolic Activity Predicts Survival after Intra-arterial Resin-Based 90Y Radioembolization Therapy in Unresectable Chemorefractory Metastatic Colorectal Cancer to the Liver. / Edalat, Faramarz; Camacho, Juan C.; Kokabi, Nima; Tuba Kendi, Ayse; Galt, James R.; Kim, Hyun S.

In: Clinical nuclear medicine, Vol. 41, No. 2, 01.02.2016, p. e76-e81.

Research output: Contribution to journalArticle

@article{f9e7c966221e4a95bbac9946969d3fa6,
title = "Standardized Added Metabolic Activity Predicts Survival after Intra-arterial Resin-Based 90Y Radioembolization Therapy in Unresectable Chemorefractory Metastatic Colorectal Cancer to the Liver",
abstract = "Purpose Standardized added metabolic (SAM) activity is a functional objective measurement of the total tumoral metabolic activity that avoids partial volume effect and thresholding, which limit conventional PET parameters. The purpose of this study is to investigate the role of SAM in predicting survival in unresectable, chemorefractory colorectal hepatic metastatic disease treated with resin-based 90Y radioembolization. Materials and Methods This is a prospective correlative study of patients with unresectable, chemorefractory colorectal liver metastasis who underwent 18F-FDG PET/CT and CT/MRI before and after 90Y. Target RECIST, PERCIST, change in total glycolytic activity (ΔTGA), and ΔSAM treatment response were assessed. Percentage changes in diameter, SUVpeak, TGA, and SAM were calculated pre-and post-90Y therapy and objective response was defined as >30{\%} change (responders). Survival analysis by Kaplan-Meier, log-rank, and Cox proportional hazard models were performed and significance was set at <0.05. Results Sixteen patients (mean age of 61.6) were enrolled and performed a total of 20 90Y therapies. After 90Y, target ΔSAM showed an objective response rate of 40{\%} vs. 35{\%}, 30{\%}, and 22.2{\%} based on target ΔTGA, PERCIST, and RECIST criteria, respectively. Median overall survival (OS) of the cohort after 90Y was 9.2 months (CI 95{\%} 2.2-16.2). Patients demonstrating objective response based on ΔSAM had a median OS of 22.7 months (CI 95{\%} 12.4-33.0) vs. 6.7 (CI 95{\%} 4.2-9.2) in non-responders (P = 0.007). On multivariate analysis, hazard ratios for the objective response group based on target ΔSAM were 0.01 (P = 0.03) vs. 0.05 (P = 0.08), 0.20 (P = 0.29), and 0.91 (P = 0.98) based on target ΔTGA, PERCIST, and RECIST criteria, respectively. Conclusions In unresectable colorectal liver metastatic disease refractory to standard chemotherapy, ΔSAM predicted OS for assessment of response following 90Y radioembolization therapy, whereas RECIST, PERCIST, and ΔTGA did not.",
keywords = "Y radioembolization, colorectal cancer, PET, standardized added metabolic activity",
author = "Faramarz Edalat and Camacho, {Juan C.} and Nima Kokabi and {Tuba Kendi}, Ayse and Galt, {James R.} and Kim, {Hyun S.}",
year = "2016",
month = "2",
day = "1",
doi = "10.1097/RLU.0000000000000991",
language = "English (US)",
volume = "41",
pages = "e76--e81",
journal = "Clinical Nuclear Medicine",
issn = "0363-9762",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Standardized Added Metabolic Activity Predicts Survival after Intra-arterial Resin-Based 90Y Radioembolization Therapy in Unresectable Chemorefractory Metastatic Colorectal Cancer to the Liver

AU - Edalat, Faramarz

AU - Camacho, Juan C.

AU - Kokabi, Nima

AU - Tuba Kendi, Ayse

AU - Galt, James R.

AU - Kim, Hyun S.

PY - 2016/2/1

Y1 - 2016/2/1

N2 - Purpose Standardized added metabolic (SAM) activity is a functional objective measurement of the total tumoral metabolic activity that avoids partial volume effect and thresholding, which limit conventional PET parameters. The purpose of this study is to investigate the role of SAM in predicting survival in unresectable, chemorefractory colorectal hepatic metastatic disease treated with resin-based 90Y radioembolization. Materials and Methods This is a prospective correlative study of patients with unresectable, chemorefractory colorectal liver metastasis who underwent 18F-FDG PET/CT and CT/MRI before and after 90Y. Target RECIST, PERCIST, change in total glycolytic activity (ΔTGA), and ΔSAM treatment response were assessed. Percentage changes in diameter, SUVpeak, TGA, and SAM were calculated pre-and post-90Y therapy and objective response was defined as >30% change (responders). Survival analysis by Kaplan-Meier, log-rank, and Cox proportional hazard models were performed and significance was set at <0.05. Results Sixteen patients (mean age of 61.6) were enrolled and performed a total of 20 90Y therapies. After 90Y, target ΔSAM showed an objective response rate of 40% vs. 35%, 30%, and 22.2% based on target ΔTGA, PERCIST, and RECIST criteria, respectively. Median overall survival (OS) of the cohort after 90Y was 9.2 months (CI 95% 2.2-16.2). Patients demonstrating objective response based on ΔSAM had a median OS of 22.7 months (CI 95% 12.4-33.0) vs. 6.7 (CI 95% 4.2-9.2) in non-responders (P = 0.007). On multivariate analysis, hazard ratios for the objective response group based on target ΔSAM were 0.01 (P = 0.03) vs. 0.05 (P = 0.08), 0.20 (P = 0.29), and 0.91 (P = 0.98) based on target ΔTGA, PERCIST, and RECIST criteria, respectively. Conclusions In unresectable colorectal liver metastatic disease refractory to standard chemotherapy, ΔSAM predicted OS for assessment of response following 90Y radioembolization therapy, whereas RECIST, PERCIST, and ΔTGA did not.

AB - Purpose Standardized added metabolic (SAM) activity is a functional objective measurement of the total tumoral metabolic activity that avoids partial volume effect and thresholding, which limit conventional PET parameters. The purpose of this study is to investigate the role of SAM in predicting survival in unresectable, chemorefractory colorectal hepatic metastatic disease treated with resin-based 90Y radioembolization. Materials and Methods This is a prospective correlative study of patients with unresectable, chemorefractory colorectal liver metastasis who underwent 18F-FDG PET/CT and CT/MRI before and after 90Y. Target RECIST, PERCIST, change in total glycolytic activity (ΔTGA), and ΔSAM treatment response were assessed. Percentage changes in diameter, SUVpeak, TGA, and SAM were calculated pre-and post-90Y therapy and objective response was defined as >30% change (responders). Survival analysis by Kaplan-Meier, log-rank, and Cox proportional hazard models were performed and significance was set at <0.05. Results Sixteen patients (mean age of 61.6) were enrolled and performed a total of 20 90Y therapies. After 90Y, target ΔSAM showed an objective response rate of 40% vs. 35%, 30%, and 22.2% based on target ΔTGA, PERCIST, and RECIST criteria, respectively. Median overall survival (OS) of the cohort after 90Y was 9.2 months (CI 95% 2.2-16.2). Patients demonstrating objective response based on ΔSAM had a median OS of 22.7 months (CI 95% 12.4-33.0) vs. 6.7 (CI 95% 4.2-9.2) in non-responders (P = 0.007). On multivariate analysis, hazard ratios for the objective response group based on target ΔSAM were 0.01 (P = 0.03) vs. 0.05 (P = 0.08), 0.20 (P = 0.29), and 0.91 (P = 0.98) based on target ΔTGA, PERCIST, and RECIST criteria, respectively. Conclusions In unresectable colorectal liver metastatic disease refractory to standard chemotherapy, ΔSAM predicted OS for assessment of response following 90Y radioembolization therapy, whereas RECIST, PERCIST, and ΔTGA did not.

KW - Y radioembolization

KW - colorectal cancer

KW - PET

KW - standardized added metabolic activity

UR - http://www.scopus.com/inward/record.url?scp=84955180490&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84955180490&partnerID=8YFLogxK

U2 - 10.1097/RLU.0000000000000991

DO - 10.1097/RLU.0000000000000991

M3 - Article

C2 - 26447380

AN - SCOPUS:84955180490

VL - 41

SP - e76-e81

JO - Clinical Nuclear Medicine

JF - Clinical Nuclear Medicine

SN - 0363-9762

IS - 2

ER -